A 5-year-old girl with known generalized tonic-clonic epilepsy on sodium valproate presents with status epilepticus. She received lorazepam 4 mg IV 10 minutes ago, but seizures have not stopped. She is now intubated and on mechanical ventilation. Vital signs: HR 140/min, BP 95/60 mmHg, temperature 39.2°C, SpO₂ 98% on FiO₂ 0.6. What is the most appropriate next step in management?

Explanation

## Refractory Status Epilepticus: Second-Line Management **Key Point:** Refractory SE is defined as SE that persists despite adequate doses of first-line benzodiazepines. This child has received lorazepam but continues seizing at 10 minutes—she now requires a second-line antiepileptic drug (AED) before escalation to continuous infusions. ### Stepwise Approach to Refractory SE ```mermaid flowchart TD A["SE persists after benzodiazepine"]:::outcome --> B["Second-line AED<br/>within 5-10 min"]:::action B --> C{"Which agent?"}:::decision C -->|"Preferred: Levetiracetam"|D["LEV 20-30 mg/kg IV"]:::action C -->|"Alternative: Phenytoin"|E["PHT 15-20 mg/kg IV"]:::action C -->|"Alternative: Valproate"|F["VPA 20-40 mg/kg IV"]:::action D --> G{"Seizure stopped?"}:::decision E --> G F --> G G -->|"Yes"| H["Identify cause, maintenance"]:::outcome G -->|"No (after 15-20 min)"|I["Continuous infusion<br/>Propofol/Midazolam"]:::urgent I --> J["ICU monitoring, EEG"]:::urgent ``` **High-Yield:** **Second-line AED Selection in Pediatric SE:** | Agent | Dose | Onset | Advantages | Disadvantages | |-------|------|-------|------------|---------------| | **Levetiracetam** | 20–30 mg/kg IV | 5–10 min | No drug interactions, renal clearance, safe in hepatic disease | Behavioral side effects (rare in acute) | | Phenytoin | 15–20 mg/kg IV | 10–20 min | Rapid onset | Risk of hypotension, arrhythmias, tissue necrosis if extravasation | | Valproate | 20–40 mg/kg IV | 5–10 min | Rapid onset | Hepatotoxicity risk, teratogenicity, pancreatitis | **Clinical Pearl:** Levetiracetam is increasingly preferred as second-line in pediatric SE because: 1. **No drug interactions** with valproate (her baseline AED)—can be used safely. 2. **Rapid IV onset** (5–10 minutes) comparable to phenytoin. 3. **No cardiovascular monitoring** required (unlike phenytoin). 4. **Renal clearance**—safe even if hepatic function is compromised. ### Why NOT Phenytoin in This Case Although phenytoin is a traditional second-line agent, it is **suboptimal here** because: - She is already on valproate; phenytoin may increase valproate levels (protein displacement). - Hypotension (current BP 95/60) contraindicates rapid IV phenytoin infusion. - Levetiracetam avoids these interactions and is equally effective. **Warning:** Do NOT skip the second-line AED phase. Going directly to continuous infusions (propofol/midazolam) without attempting a second-line AED is incorrect—the ILCM algorithm mandates a 15–20 minute window for second-line drugs before escalation to ICU-level management. ### Role of Continuous Infusions Propofol or midazolam infusions are reserved for **refractory SE** (persisting after benzodiazepine + second-line AED, typically >20–30 minutes). This child is still in the second-line phase and should not yet be on continuous infusions. [cite:Nelson Textbook of Pediatrics 21e Ch 609; International League Against Epilepsy Status Epilepticus Guidelines 2017]